This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

AboutAboutSerotypesMechanism of ActionCAPiTA: Prevnar 13 Efficacy profileImmunogenicity profileSafety profilePatient profilesDosingDosingDosingPneumococcal diseasePneumococcal diseasePneumococcal diseasePneumococcal serotypesRisk factorsRecommendationsRecommendationsRecommendationsResourcesResourcesMaterialsVideos
Important Safety InformationProduct Monograph
Pneumococcal serotypesDistribution of serotypes in Canada*Invasive S. pneumoniae serotypes, percentage of isolates 20221-4*
Serotype 2022 Percentage Distribution (all ages)
1 0.1%
3 11.9%
4 12.4%
6A 0.1%
6B 0.2%
7F 2.3%
9V 5.1%
14 0.2%
18C 0.3%
19A 5.9%
19F 2.8%
23F 0.3%
22F 7.3%
33F 1.4%
8 5.1%
10A 1.3%
11A 3.2%
12F 5.4%
15B/C 3.2%
2 0.0%
9N 5.2%
17F 0.6%
20 4.4%
6C 1.5%
15A 2.9%
16F 2.2%
23A 2.9%
23B 2.8%
24F 0.2%
31 1.5%
35B 1.8%
7C 1.5%
13 0.3%
21 0.3%
28A 0.3%
34 0.9%
35F 1.6%
38 0.1%
Nontypeable 0.1%
Other 0.8%
Adapted from Public Health Agency of Canada.Vaccine preventable serotypes1-4PREVNAR 13 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23FPREVNAR 20 serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33FAll vaccine-preventable serotypes: 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19A, 19F, 20, 22F, 23A, 23B, 23F, 24F, 31, 33F, 35BNon-vaccine preventable serotypes: 7C, 13, 21, 28A, 29, 34, 35F, 38
  • The serotypes included in PREVNAR 13 accounted for 41.6% of invasive pneumococcal disease cases in all ages, while the additional serotypes included in PREVNAR 20 accounted for a further 26.9%.1
  • In 2022, serotypes 4 (14.9%) and 3 (14.6%) were the most common in 50 to 64-year-olds, while serotypes 3 (13.3%) and 22F (9.9%) were dominant in adults over 65 years of age.
  • Of the over 100 identified serotypes, those included in PREVNAR 20 have been associated with higher case-fatality rates and mortality, antibiotic resistance, meningitis and outbreaks.3
A study from the National laboratory surveillance of invasive streptococcal disease in Canada examining the serotype distribution of 3775 isolates of invasive pneumococcal disease1References:Public Health Agency of Canada. Invasive pneumococcal disease surveillance in Canada, 2021-2022. May 2024. Accessed on June 17, 2024.CAPVAXIVE Product Monograph. Merck Canada ULC.PREVNAR 20 Product Monograph. Pfizer Canada ULC.PNEUMOVAX 23 Product Monograph. Merck Canada ULC. NEXT

Risk Factor

 Visit page Loading
PP-PNR-CAN-0140. November 2024

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN